Integra LifeSciences
IART
TypePublic
IndustryMedical technology
Founded1989 [1]
HeadquartersPrinceton, New Jersey
Key people
Jan De Witte, CEO[2]
Products
Revenue$1.3 billion (2020)[1]
Number of employees
3,700 (2020)[1]
Websiteintegralife.com

Integra LifeSciences is a global medical device manufacturing company headquartered in Princeton, New Jersey.[3][4] Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery.[3] Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.[5][6]

History

Integra LifeSciences was founded by Richard Caruso in 1989 after Caruso licensed Integra artificial skin technology from Harvard–MIT and acquired Colla-tec, a subsidiary of Marion Laboratories.[3][7] The company became publicly traded under the NASDAQ ticker name IART.[7]

In 1996, Integra artificial skin was approved by the U.S. Food and Drug Administration.[8] The artificial skin, manufactured and patented as Integra, is now used on patients with extensive burns.[5] In 1999, the FDA approved Integra LifeSciences’ DuraGen, an absorbable implant used in neurosurgical and spinal procedures.[9]

In 2001, the company received FDA approval for Licox, a brain tissue oxygen and temperature monitor.[10][11] Licox is used to treat patients in critical care, including those suffering from traumatic brain injuries.[10]

In 2002, the FDA approved the use of Integra Dermal Regeneration Template for reconstructive surgery of burn scars.[12] In 2016, IDRT received premarket approval from the FDA for the treatment of diabetic foot ulcers.[13]

In 2018, Integra LifeSciences was included in Fortune’s list of Fastest Growing Companies.[14]

In 2023, Integra ranked #59 on Medical Design and Outsourcing’s list of largest medical technology companies in the world.[15]

Integra artificial skin

In 1969, John F. Burke, a surgeon and Harvard Medical School professor, and Ioannis V. Yannas, a mechanical engineering professor of fibers and polymers at MIT, began working on a new form of artificial skin.[5] They created the first commercially reproducible artificial skin, later patented and manufactured as Integra.[5]

Integra is used to treat patients with severe burns.[5][6][8] The top layer, made of thin silicone, protects the patient from infection and dehydration, common causes of death after being severely burned.[5][8] The bottom layer, made of animal tissue, acts as scaffolding where new skin will grow.[5][16] Compared to traditional skin grafts, the use of Integra reduces pain and scarring.[5][8][16][6]

Integra is also used in plastic surgery, reconstructive surgery, and to treat some forms of cancer and other skin wounds.[6][17][18][19]

Acquisitions

In October 2014, Integra LifeSciences acquired instrumentation lines from Medtronic for $60 million.[20] In January 2014, the company bought Covidien’s Confluent Surgical line of sealants and shields.[21]

In July 2015, Integra LifeSciences acquired TEI Biosciences and TEI Medical and began manufacturing their SurgiMend and PriMatrix product lines.[22][23] Primatrix, a dermal repair scaffolding product, is used to treat diabetic foot ulcers, burns, and in other procedures.[24][25]

In January 2017, Integra Lifesciences acquired Derma Sciences for $204 million.[26] Their TCC-EZ Total Contact Cast, used to treat diabetic foot ulcers, reduces pressure and shortens application time compared to a conventional total contact cast.[26][27][28]

In October 2017, Integra LifeSciences acquired Johnson & Johnson’s Codman Neurosurgery business for $1.045 billion.[29] The Codman Hakim valve was developed as a new way to treat hydrocephalus.[30][31]

In January 2021, the company acquired regenerative medicine firm, ACell, for $400M.[32][33]

References

  1. 1 2 3 https://investor.integralife.com/static-files/2b15533d-3c34-4583-991c-86139e821468
  2. "Integra Lifesciences announces new CEO". 28 October 2021.
  3. 1 2 3 Trenton, Joyce J. Persico | For The Times of (2011-09-30). "Integra upgrades Plainsboro office for skin regeneration market". nj. Retrieved 2021-10-12.
  4. "Integra LifeSciences Celebrates New Global Headquarters". New Jersey Business Magazine. Retrieved 2021-10-12.
  5. 1 2 3 4 5 6 7 8 Vitello, Paul (2011-11-05). "Dr. John F. Burke, Dies at 89; Created Synthetic Skin". The New York Times. ISSN 0362-4331. Retrieved 2021-10-08.
  6. 1 2 3 4 "New healing, hope for burn victims | The Seattle Times". archive.seattletimes.com. Retrieved 2021-10-08.
  7. 1 2 Crosby, John C. (2019-06-13). Built to Help Each Other: Mentoring in the Life of Richard Caruso: An Uncommon Man. Radius Book Group. ISBN 978-1-63576-708-7.
  8. 1 2 3 4 Schaffer, Amanda (2006-05-02). "Cadaver Skin Fills the Gap in Burn Cases". The New York Times. ISSN 0362-4331. Retrieved 2021-10-14.
  9. "Integra Lifesciences Cleared to Market New Dural Graft Matrix". www.meddeviceonline.com. Retrieved 2021-10-14.
  10. 1 2 Stewart, Campbell (December 1, 2008). "The New Licox Combined Brain Tissue Oxygen and Brain Temperature Monitor". Neurosurgery. 63 (6): 1159–1165. doi:10.1227/01.NEU.0000333265.19131.7C. PMID 19057329. S2CID 33380827 via Oxford Academic.
  11. Layon, Joseph A.; Gabrielli, Andrea; Friedman, William A. (2013). Textbook of Neurointensive Care. Springer. p. 135. ISBN 978-1-4471-5225-5.
  12. "FDA approves Integra Omnigraft Dermal Regeneration Matrix to treat diabetic foot ulcers". FDA. 2018-11-03. Retrieved 2021-10-14.
  13. "Premarket Approval (PMA)". www.accessdata.fda.gov. Retrieved 2021-10-14.
  14. "Inside Fortune's 2018 Fastest-Growing Companies List". Fortune. Retrieved 2022-03-01.
  15. "The 2023 Medtech Big 100: The world's largest medical device companies". Medical Design and Outsourcing. Retrieved 2023-09-03.
  16. 1 2 FDA Consumer 2002-06: Vol 36 Iss 3. Internet Archive. Superintendent of Documents. June 2002.{{cite book}}: CS1 maint: others (link)
  17. Thinda, Sumeer; Wright, Harry V.; Mawn, Louise A. (February 2012). "Integra Bilayer Matrix Wound Dressing Closure of Large Periorbital Traumatic Wound". Arch Ophthalmol. 130 (2): 217–219. doi:10.1001/archopthalmol.2011.1178. PMID 22332215 via JAMA Network.
  18. Chang, Daniel K.; Louis, Matthew R.; Gimenez, Alejandro; Reece, Edward M. (August 2, 2019). "The Basics of Integra Dermal Regeneration Template and its Expanding Clinical Applications". Seminars in Plastic Surgery. 33 (3): 185–189. doi:10.1055/s-0039-1693401. PMC 6680073. PMID 31384234.
  19. Chalmers, R L; Smock, E; Geh, J L C (March 23, 2010). "Experience of Integra(®) in cancer reconstructive surgery". Journal of Plastic, Reconstructive & Aesthetic Surgery. 63 (12): 2081–2090. doi:10.1016/j.bjps.2010.02.025. PMID 20335086 via National Library of Medicine.
  20. "Integra LifeSciences closes MicroFrance, Xomed buy from Medtronic". MassDevice. October 27, 2014.
  21. "Covidien closes $235M divestiture of Confluent to Integra LifeSciences". MassDevice. January 16, 2014. Retrieved 2022-01-19.
  22. "Integra LifeSciences Completes Acquisition Of TEI Biosciences, TEI Medical". www.meddeviceonline.com. 2015-07-20. Retrieved 2022-02-22.
  23. "510(k) Premarket Notification". www.accessdata.fda.gov. Retrieved 2022-02-22.
  24. Karr, Jeffrey (2011). "Retrospective Comparison of Diabetic Foot Ulcer and Venous Stasis Ulcer Healing Outcome Between a Dermal Repair Scaffold (PriMatrix) and a Bilayered Living Cell Therapy (Apligraf)". Advances in Skin & Wound Care. 24 (3): 119–125. doi:10.1097/01.ASW.0000395038.28398.88. PMID 21326023. S2CID 26391378.
  25. Parcells, Alexis Lanteri; Karcich, Jenika; Granick, Mark S.; Marano, Michael A. (2014-09-24). "The Use of Fetal Bovine Dermal Scaffold (PriMatrix) in the Management of Full-Thickness Hand Burns". ePlasty. 14: e36. ISSN 1937-5719. PMC 4182964. PMID 25328569.
  26. 1 2 Hodsden, Suzanne (2017-01-13). "Integra LifeSciences Acquirers Derma Sciences for $204M, Expands Regenerative Technology Offerings". www.meddeviceonline.com. Retrieved 2022-02-17.
  27. Arnold, Jonathan F.; Marmolejo, Valerie (October 2017). "Outcomes Achieved With Use of a Prefabricated Roll-On Total Contact Cast". Foot & Ankle International. 38 (10): 1126–1131. doi:10.1177/1071100717716486. ISSN 1944-7876. PMID 28800712. S2CID 40470722.
  28. Messenger, Grace; Masoetsa, Richard; Hussain, Imtiaz (2018-06-07). "A Narrative Review of the Benefits and Risks of Total Contact Casts in the Management of Diabetic Foot Ulcers". The Journal of the American College of Clinical Wound Specialists. 9 (1–3): 19–23. doi:10.1016/j.jccw.2018.05.002. ISSN 2213-5103. PMC 6304285. PMID 30591897.
  29. Newmarker, Chris (2017-10-02). "Integra LifeSciences completes purchase of J&J's Codman Neurosurgery". MassDevice. Retrieved 2022-02-09.
  30. Gunderman, Richard; Lopez, Gloria (2019-01-17). "Who was Hakim?" (PDF). Journal of Radiology and Medical Imaging. ISSN 2637-885X via MEDDOCS Open Access Publisher.
  31. Sussman, Ph.D, Marvin (2011-05-09). "Dr. Salomon Hakim – a Giant in the Field of Hydrocephalus". Hydrocephalus Association. Retrieved 2022-02-09.
  32. "Integra LifeSciences to acquire ACell". MassDevice. 2020-12-16. Retrieved 2022-01-12.
  33. "Integra (IART) Acquires Acell, Focuses on Regenerative Space". Nasdaq. January 21, 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.